Clinical Trial Search Results for "TIMI 11B"

Antman, E. M. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators Am Heart J. 1998;135(6, Supplement 2):S353-60. Abstract

Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation. 1999;100:1593-601. Abstract

Antman, E. M., Cohen, M., Radley, D., McCabe, C., Rush, J., Premmereur, J., Braunwald, E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis Circulation. 1999;100(15):1602-8. Abstract

Antman, E. M., Cohen, M., Bernink, P. J., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., Braunwald, E. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making JAMA. 2000;284(7):835-42. Abstract

Bozovich, G. E., Gurfinkel, E. P., Antman, E. M., McCabe, C. H., Mautner, B. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time Am Heart J. 2000;140(4):637-42. Abstract

Cohen, M., Antman, E. M., Gurfinkel, E., Turpie, A. G., Furst, J., Bigonzi, F., Radley, D. Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction Am J Cardiol. 2000;86(5):553-6, A9. Abstract

Morrow, D. A., Antman, E. M., Tanasijevic, M., Rifai, N., de Lemos, J. A., McCabe, C. H., Cannon, C. P., Braunwald, E. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy J Am Coll Cardiol. 2000;36(6):1812-7. Abstract

Morrow, D. A., Rifai, N., Tanasijevic, M. J., Wybenga, D. R., de Lemos, J. A., Antman, E. M. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy Clin Chem. 2000;46(4):453-60. Abstract

Cohen, M., Antman, E. M., Gurfinkel, E. P., Radley, D. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups J Thromb Thrombolysis. 2001;12(3):199-206. Abstract

Henry, T. D., Satran, D., Knox, L. L., Iacarella, C. L., Laxson, D. D., Antman, E. M. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J. 2001;142(4):590-3. Abstract

Holper, E. M., Antman, E. M., McCabe, C. H., Premmereur, J., Gurfinkel, E., Bernink, P. J., Turpie, A. G., Bayes de Luna, A., Lablanche, J. M., Fox, K. M., Salein, D., Radley, D. R., Braunwald, E. A simple, readily available method for risk stratification of patients with unstable angina and non-ST elevation myocardial infarction Am J Cardiol. 2001;87(8):1008-10; A5.

Santopinto, J., Gurfinkel, E. P., Torres, V., Marcos, E., Bozovich, G. E., Mautner, B., McCabe, C. H., Antman, E. M. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin Am Heart J. 2001;141(4):566-72. Abstract

Antman, E. M., Cohen, M., McCabe, C., Goodman, S. G., Murphy, S. A., Braunwald, E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE Eur Heart J. 2002;23(4):308-14. Abstract

Becker, R. C., Spencer, F. A., Gibson, M., Rush, J. E., Sanderink, G., Murphy, S. A., Ball, S. P., Antman, E. M. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J. 2002;143(5):753-9. Abstract

Cohen, M., Antman, E. M., Murphy, S. A., Radley, D. Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes Am Heart J. 2002;143(1):63-9. Abstract

Fox, K. A., Antman, E. M., Cohen, M., Bigonzi, F. Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention Am J Cardiol. 2002;90(5):477-82. Abstract

Morrow, D. A., Antman, E. M., Snapinn, S. M., McCabe, C. H., Theroux, P., Braunwald, E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS Eur Heart J. 2002;23(3):223-9. Abstract

Omland, T., de Lemos, J. A., Morrow, D. A., Antman, E. M., Cannon, C. P., Hall, C., Braunwald, E. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes Am J Cardiol. 2002;89(4):463-5.

Sabatine, M. S., McCabe, C. H., Morrow, D. A., Giugliano, R. P., de Lemos, J. A., Cohen, M., Antman, E. M., Braunwald, E. Identification of patients at high risk for death and cardiac ischemic events after hospital discharge Am Heart J. 2002;143(6):966-70. Abstract

de Lemos, J. A., Morrow, D. A., Gibson, C. M., Murphy, S. A., Sabatine, M. S., Rifai, N., McCabe, C. H., Antman, E. M., Cannon, C. P., Braunwald, E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies J Am Coll Cardiol. 2002;40(2):238-44. Abstract

Spinler, S. A., Inverso, S. M., Cohen, M., Goodman, S. G., Stringer, K. A., Antman, E. M. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies Am Heart J. 2003;146(1):33-41. Abstract

Petersen, J. L., Mahaffey, K. W., Hasselblad, V., Antman, E. M., Cohen, M., Goodman, S. G., Langer, A., Blazing, M. A., Le-Moigne-Amrani, A., de Lemos, J. A., Nessel, C. C., Harrington, R. A., Ferguson, J. J., Braunwald, E., Califf, R. M. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview JAMA. 2004;292(1):89-96. Abstract

Yeh, R. W., Wiviott, S. D., Giugliano, R. P., Morrow, D. A., Shui, A., Qin, J., Scirica, B., Bradner, J. E., Jang, I. K., Gibson, C. M., Antman, E. M. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes Am J Cardiol. 2007;100(12):1734-8. Abstract